Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the results of clinical trial of carfilzomib, lenalidomide, cyclophosphamide and dexamethasone. This drug combination turned out to be one of the most efficacious and low toxicity induction treatments for young multiple myeloma patients, as 15-20% of patients achieved complete remission (CR) before they receive a transplant.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.